Questionnaire

1. Vedolizumab is an inhibitor of:

2. The LOVE-CD trial demonstrated that VDZ-treated patients with CD:

3. VDZ-treated patients with CD and assessed by video capsule endoscopy demonstrated significant pan-enteric MH at:

4. A Japanese 52-week real-world study of patients with UC found that VDZ treatment resulted in higher clinical remission rates in patients who were:

5. During VDZ treatment, quality of life PROs in patients with moderate-to-severe UC and CD showed improvement from:

6. Among patients with UC or CD, the LIVE Extension study of VDZ therapy beyond five years demonstrated that:

7. In biologic-naïve patients with moderate-to-severe UC, retrospective real-world UK data demonstrated that:

8. The EVOLVE expansion study demonstrated at 36 months that clinical response, clinical remission, MH and treatment persistence was similar between biologic-naïve patients with CD and treated with VDZ or UST.

9. After anti-TNF treatment failure in patients with UC, treatment using VDZ or UST demonstrated comparable one-year rates of:

10. In anti-TNF-experienced patients with CD, drug persistence was: